Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 155   

Articles published

BMY 61.46 +0.24 (0.39%)
price chart
Buzz Stocks: Ocwen Financial Corporation, Bristol-Myers Squibb Company, and ...
The shares of Bristol-Myers Squibb Co are sitting at $60.52 -- up 11.8% year-over-year, and just north of support at their 80-day moving average.
Bristol-Myers Squibb Co To Acquire Flexus Pharmaceuticals And Partner With ...
Bristol-Myers Squibb's head of discovery and R&D, Carl Decicco, expressed his views on the recent partnership deal and stated: �As a company dedicated to leading scientific advances in immuno-oncology, we are committed to exploring the utility of TGF ...
Jacobs Awarded Contract from Bristol-Myers Squibb (press release)
Today's Hot Stocks: National Bank of Greece (ADR) (NYSE:NBG), Rigel ...  Markets Emerging
Investors Buy Shares of Bristol-Myers Squibb on Weakness (BMY)
Finally, analysts at Barclays raised their price target on shares of Bristol-Myers Squibb from $46.00 to $55.00 and gave the company an �equal weight� rating in a research note on Friday, January 16th. One equities research analyst has rated the stock ...
Zacks Reiterates Neutral Rating for Bristol-Myers Squibb (BMY)  Dakota Financial News
Analyst Rating Update on Bristol-Myers Squibb Co  Stafford Daily
An Insider Lamberto Andreotti Sold 90246 of Bristol-Myers Squibb Co (NYSE:BMY)
A legal document filed with the D.C. based-SEC on February 02, 2015 made public that Lamberto Andreotti, the Chief Executive Officer of Bristol-Myers Squibb Co (NYSE:BMY) 61.29 +0.77 1.27% , Chemical Manufacturing's company sold 90,246 shares.
Zacks Rating Disclosure on Bristol-Myers Squibb Co  Stafford Daily
Bristol-Myers Squibb CEO Lamberto Andreotti Sells 90246 Shares (BMY)  Dakota Financial News
Bristol-Myers Squibb's Neutral Rating Reaffirmed at Zacks (BMY)
Bristol-Myers Squibb has a 52-week low of $46.30 and a 52-week high of $64.44. The stock has a 50-day moving average of $60.77 and a 200-day moving average of $55.99.
5 Things Bristol-Myers Squibb Co.'s Management Wants You to Know
Bristol-Myers Squibb's (NYSE: BMY ) dramatic reorganization effort, following the loss of patent protection for several top-selling drugs, appears to be hitting an inflection point.
Inside Trade: James Cornelius Sold 50000 Shares of Bristol-Myers Squibb Co ...
Bristol-Myers Squibb Director Sells $152225.00 in Stock (BMY)  Dakota Financial News
Share Price of Bristol-Myers Squibb Co Rally 0.62%
Shares of Bristol-Myers Squibb Co (NYSE:BMY) appreciated by 0.62% during the past week but lost 3.64% on a 4-week basis. The shares are however, marginally negative as compared to the S&P 500 for the past week with a loss of 1.37%.
Bristol-Myers Squibb Co Analyst Rating Update  Stafford Daily
Sandra Leung Sells 11746 Shares of Bristol-Myers Squibb Stock (BMY)  Dakota Financial News
Bristol-Myers Squibb to Present at Cowen and Company Annual Global Health ...
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will present at the Cowen and Company 35th Annual Global Health Care Conference on Tuesday, March 3, 2015, in Boston.
Bristol-Myers Squibb Co (BMY) Releases FY15 Earnings Guidance
Bristol-Myers Squibb logo Bristol-Myers Squibb Co (NYSE:BMY) issued an update on its FY15 earnings guidance on Tuesday morning.
Barclays Rating Disclosure on Bristol-Myers Squibb Co  Stafford Daily
Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc
Case Name: Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc., 769 F.3d 1339 (Fed. Cir. Oct. 20, 2014) (Chief Judge Prost, Circuit Judges Newman, Plager, Lourie, Dyk, Moore, O'Malley, Reyna, Wallach, Taranto, Chen, and Hughes presiding; per curiam ...